European Journal of Internal Medicine最新文献_第6页

Association of prevalence of hypertension and its subtypes with short-term weight change. 高血压患病率及其亚型与短期体重变化的关系

IF 6.1 2区医学

European Journal of Internal Medicine Pub Date : 2025-09-25 DOI: 10.1016/j.ejim.2025.106513

Haonan Li, Jieying Shi, Jialin Wen, Juan Luo, Yi Zhang

引用次数: 0

Sodium-glucose cotransporter 2 inhibitors may increase iron availability with beneficial effects on erythropoiesis and cardiovascular mortality in patients with type 2 diabetes mellitus. Author's Reply. 钠-葡萄糖共转运蛋白2抑制剂可能增加铁的可用性，对2型糖尿病患者的红细胞生成和心血管死亡率有有益影响。作者的回答。

IF 6.1 2区医学

European Journal of Internal Medicine Pub Date : 2025-09-22 DOI: 10.1016/j.ejim.2025.106516

Rossella Cannarella, Michele Rubulotta, Vittorio Cannarella, Sandro La Vignera, Aldo E Calogero

引用次数: 0

Prognostic impact of left ventricular dilatation in heart failure with mildly reduced ejection fraction. 左心室扩张对心力衰竭伴轻度射血分数降低的预后影响。

IF 6.1 2区医学

European Journal of Internal Medicine Pub Date : 2025-09-16 DOI: 10.1016/j.ejim.2025.106510

Henning Johann Steffen, Michael Behnes, Jonas Dudda, Alexander Schmitt, Noah Abel, Felix Lau, Marielen Reinhardt, Thomas Bertsch, Kathrin Weidner, Daniel Duerschmied, Ibrahim Akin, Tobias Schupp

{"title":"Prognostic impact of left ventricular dilatation in heart failure with mildly reduced ejection fraction.","authors":"Henning Johann Steffen, Michael Behnes, Jonas Dudda, Alexander Schmitt, Noah Abel, Felix Lau, Marielen Reinhardt, Thomas Bertsch, Kathrin Weidner, Daniel Duerschmied, Ibrahim Akin, Tobias Schupp","doi":"10.1016/j.ejim.2025.106510","DOIUrl":"https://doi.org/10.1016/j.ejim.2025.106510","url":null,"abstract":"Objective: This study investigated the prognostic value of left ventricular (LV) dilatation in patients with heart failure with mildly reduced ejection fraction (HFmrEF).Background: Adverse cardiac remodeling may lead to LV dilatation and impaired prognosis in heart failure with reduced ejection fraction (HFrEF). Its significance in HFmrEF remains unclear.Methods: Patients hospitalized with HFmrEF (2016-2022) were included and stratified by the presence or absence LV dilatation (males: LV end-diastolic diameter (LVEDD) >58 mm; females: >52 mm). Kaplan-Meier and multivariable Cox regression analyses assessed 30-month all-cause mortality and HF-related rehospitalization.Results: Among 2154 patients (median LVEDD 49.0 mm), 290 (13.5 %) had LV dilatation. These patients were younger (73 vs. 76 years; p = 0.001), less often males (42.2 % vs. 67.2 %; p = 0.001), and more likely to have non-ischemic cardiomyopathy (10.0 % vs. 6.3 %; p = 0.019). LV dilatation was not associated with 30-month all-cause mortality (29.7 % vs. 31.4 %; HR = 0.933; 95 % CI 0.744-1.171; p = 0.548) but was linked to higher HF-related rehospitalization risk (19.1 % vs. 12.5 %; HR = 1.606; 95 % CI 1.193-2.161; p = 0.003), even after multivariable adjustment (HR = 1.613; 95 % CI 1.163-2.238; p = 0.004).Conclusion: In HFmrEF, LV dilatation independently predicts HF-related rehospitalization but not all-cause mortality.","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":"106510"},"PeriodicalIF":6.1,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Annual chest computed tomography in multimorbid COPD: Is universal screening clinically feasible? Author's reply. 多病性COPD的年度胸部计算机断层扫描：普遍筛查在临床上可行吗？作者的回答。

IF 6.1 2区医学

European Journal of Internal Medicine Pub Date : 2025-09-15 DOI: 10.1016/j.ejim.2025.106508

Bartolome R Celli, Leonardo M Fabbri

引用次数: 0

Anemia in cardiorenal disease: From pathogenesis to treatment. 心肾疾病中的贫血：从发病机理到治疗。

IF 6.1 2区医学

European Journal of Internal Medicine Pub Date : 2025-09-15 DOI: 10.1016/j.ejim.2025.106506

Juan Heng, Zhong-Tang Li, Dan-Dan Yao, Xin-Yan Li, Ming-Xuan Cui, Zuo-Lin Li

{"title":"Anemia in cardiorenal disease: From pathogenesis to treatment.","authors":"Juan Heng, Zhong-Tang Li, Dan-Dan Yao, Xin-Yan Li, Ming-Xuan Cui, Zuo-Lin Li","doi":"10.1016/j.ejim.2025.106506","DOIUrl":"https://doi.org/10.1016/j.ejim.2025.106506","url":null,"abstract":"Heart failure and chronic kidney disease frequently coexist, which often leads to dysfunctional state favoring the development of anemia, termed cardiorenal anemia syndrome. Emerging evidence indicated that anemia is associated with decreased quality of life and adverse clinical outcomes in cardiorenal patients. However, the underlying pathophysiology of the anemia in this population remains incompletely understood and evidence-based recommendations for the anemia management are lacking. In the present review, the pathophysiology of anemia in cardiorenal patients and the management of anemia are discussed. Accordingly, the reduction of endogenous erythropoietin (EPO), the dysregulation of ion metabolism and increased hepcidin levels, bone marrow unresponsiveness to EPO, inactivation of EPO receptors, nutritional deficiencies caused by gastrointestinal dysfunction, shortened red blood cell life span, and inhibition of hematopoietic activity caused by medication are some of the underlying mechanisms of anemia in patient with HF and CKD. Therapeutically, hypoxia-inducible factor-prolyl hydroxylase inhibitors appear to exhibit unique advantages in managing anemia in cardiorenal patients. Intravenous iron supplementation may effectively and safely treat anemia in cardiorenal patients. Sodium-glucose cotransporter 2 inhibitors are indicated in the cardiorenal patients because of their cardiorenal benefit and additionally offer mild increases in hemoglobin/hematocrit that can help to correct or delay progression of anemia in these patients, but not in advanced CKD. However, although erythropoiesis stimulating agents use may be still a common strategy in dialysis patients, the evidence regarding the use of ESAs in cardiorenal patients is limited. Notably, further research is needed to optimize anemia management strategies in cardiorenal patients.","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":"106506"},"PeriodicalIF":6.1,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Age, sex and DNAR: Re-evaluating the excess-mortality paradox in nonagenarian ICU patients. 年龄、性别和DNAR：重新评估老年ICU患者的超额死亡率悖论。

IF 6.1 2区医学

European Journal of Internal Medicine Pub Date : 2025-09-15 DOI: 10.1016/j.ejim.2025.106466

Renyi Zhu, Jianmin Qu

引用次数: 0

Evaluation of cognitive profile and subclinical vascular damage in subjects with genetically confirmed familial hypercholesterolemia. 评估遗传证实的家族性高胆固醇血症患者的认知特征和亚临床血管损伤。

IF 6.1 2区医学

European Journal of Internal Medicine Pub Date : 2025-09-15 DOI: 10.1016/j.ejim.2025.106511

Sabrina Scilletta, Nicoletta Miano, Maurizio Di Marco, Marco Musmeci, Salvatore Carasi, Stefania Capuccio, Claudia Pistritto, Caterina Ippolito, Mariapaola Tiralongo, Antonio Ricci, Maria Chiara Papa, Giosiana Bosco, Francesco Di Giacomo Barbagallo, Antonino Di Pino, Salvatore Piro, Roberto Scicali

{"title":"Evaluation of cognitive profile and subclinical vascular damage in subjects with genetically confirmed familial hypercholesterolemia.","authors":"Sabrina Scilletta, Nicoletta Miano, Maurizio Di Marco, Marco Musmeci, Salvatore Carasi, Stefania Capuccio, Claudia Pistritto, Caterina Ippolito, Mariapaola Tiralongo, Antonio Ricci, Maria Chiara Papa, Giosiana Bosco, Francesco Di Giacomo Barbagallo, Antonino Di Pino, Salvatore Piro, Roberto Scicali","doi":"10.1016/j.ejim.2025.106511","DOIUrl":"https://doi.org/10.1016/j.ejim.2025.106511","url":null,"abstract":"Background: Familial hypercholesterolemia (FH) is characterized by elevated LDL cholesterol (LDL-C) levels that promote atherosclerosis progression. Limited data exist on the link between elevated LDL-C and cognitive impairment. The aim of this study was to assess the prevalence of cognitive impairment in FH subjects and its association with subclinical vascular damage.Methods: In this cross-sectional observational study, we evaluated 253 genetically confirmed FH subjects aged between 18 and 75 years and without previous documented cognitive disorders. Clinical evaluation, biochemical analyses and vascular profile assessment were obtained from all subjects. Cognitive function was assessed using the Short Blessed Test (SBT). Participants were stratified into two groups according to SBT: normal cognition (NC) group (n = 202) and impaired cognition (IC) group (n = 51).Results: The IC group was older and had higher prevalence of hypertension than the NC group. Dutch Lipid Clinical Network (DLCN) score at diagnosis was higher in the IC group than the NC group. Pulse wave velocity (PWV) and intima-media thickness (IMT) were significantly elevated in the IC group than the NC group (PWV: 8.64±0.43 vs 7.24±0.13 m/s, p = 0.0001; IMT: 0.78±0.02 vs 0.68±0.01 mm, p = 0.0003). Logistic regression showed that cognitive impairment was independently associated with increased PWV (OR 1.32 [1.06-1.66], p = 0.012).Conclusions: FH subjects with cognitive impairment exhibited increased PWV and IMT. These findings suggest that subclinical vascular damage may independently contribute to the cognitive decline in FH subjects.","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":"106511"},"PeriodicalIF":6.1,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond eligibility - the relevance of individualized heart failure therapy across specialties. 超越资格-跨专业个体化心力衰竭治疗的相关性。

IF 6.1 2区医学

European Journal of Internal Medicine Pub Date : 2025-09-12 DOI: 10.1016/j.ejim.2025.106507

Henning Johann Steffen, Tobias Schupp

引用次数: 0

Treatment target of blood pressure: Changes in evidence-based guidelines and impact of measurement conditions. 血压的治疗目标：循证指南的变化和测量条件的影响。

IF 6.1 2区医学

European Journal of Internal Medicine Pub Date : 2025-09-08 DOI: 10.1016/j.ejim.2025.106501

Kei Asayama, Takayoshi Ohkubo

引用次数: 0

Not all immunosuppression is equal: Implications for post-discharge outcomes in community-acquired pneumonia. 并非所有免疫抑制都是平等的：对社区获得性肺炎出院后结局的影响。